Author Archives: Lu Rahman

#AI / data analytics / healthtech / informatics #Drug development #Drug discovery #Oncology #Therapeutics

Lantern Pharma AI milestone will cut cost, time and risk in developing new drug therapies

Lantern Pharma has reached a significant milestone by surpassing one billion curated data points on its RADR platform, a total it believes is the most amassed by any company in the biotech sector. The milestone, which was reached well ahead of schedule, enables new opportunities in Lantern’s work to identify and… Read More

#News

#Clinical trials #Covid-19 #Vaccines

Pfizer and BioNTech conclude Phase III study of Covid-19 vaccine, showing 95% efficacy

Pfizer and BioNTech have announced that after conducting the final efficacy analysis in their ongoing Phase III study, their mRNA-based COVID-19 vaccine candidate, BNT162b2, met all of the study’s primary efficacy endpoints. Analysis of the data indicates a vaccine efficacy rate of 95% in participants without prior SARS-CoV-2 infection (first… Read More

#Covid-19 #Editor's Choice #News #Trending News

#AI / data analytics / healthtech / informatics #Clinical trials #Drug development #Therapeutics

First patient recruited for novel precision medicine trial for patients with hypertension

Closed Loop Medicine (CLM) a clinical stage therapeutics company developing drug and digital combination products, has recruited the first patient into its pivotal clinical trial investigating CLM’s integrated precision care solution for patients with hypertension. The clinical trial, called Personal COVID BP, will see up to 1,000 patients recruited for… Read More

#News

#AI / data analytics / healthtech / informatics #Genetics / genomics

Bayer begins new G4A Digital Health Partnerships program

Decipher Biosciences is one of five new startup companies being supported by Bayer as part of its G4A Digital Health Partnerships Program. Decipher Biosciences offers a portfolio of genomic tests, is building the GRID database of over 85,000 whole transcriptome profiles, and is partnering with pharmaceutical companies to identify biomarkers… Read More

#News

#Covid-19 #Immunology / Virology & Vaccines

European Medicines Agency begins rolling review of Moderna’s vaccine candidate

The European Medicines Agency (EMA) human medicines committee (CHMP) has started a rolling review of Moderna’s mRNA-1273 vaccine candidate against COVID-19. This follows confirmation of eligibility of mRNA-1273 for submission on October 14, 2020. On 16 November Moderna announced that the independent, US NIH-appointed Data Safety Monitoring Board (DSMB) for… Read More

#Covid-19 #News

#Covid-19 #Immunology / Virology & Vaccines

Moderna announces supply agreement with UK government for COVID-19 vaccine

Moderna has announced a supply agreement with the UK government to supply mRNA-1273, its COVID-19 vaccine candidate, beginning in March 2021 if it is approved for use by UK regulatory authorities. This agreement comes as the UK continues its efforts to secure access to safe and effective COVID-19 vaccines. “We… Read More

#Covid-19 #Editor's Choice #News #Trending News

#Biotechnology #Oncology #Therapeutics

STORM Therapeutics uses Evotec platform to push oncology project towards clinical studies

STORM Therapeutics will use INDiGO, Evotec’s integrated, accelerated IND-enabling platform, to progress its STC-15 towards an IND application in 2021. STORM, a biotechnology company focused on the discovery and development of small molecule therapies modulating RNA epigenetics, has selected STC-15 as a first-in-class development candidate. STORM discovered STC-15, an orally… Read More

#Cancer Research #News

#Analysis #Chromatography

PerkinElmer launches new HPLC, UHPLC and next generation software solution

PerkinElmer has introduced the LC 300TM platform and SimplicityChromTM software, bringing together advanced high-performance liquid chromatography (HPLC) and ultra-high performance liquid chromatography (UHPLC) capabilities with intuitive instrument control and data analysis. The new solution has been designed to accelerate throughput, streamlines testing and enable user-friendly operation to enhance productivity for… Read More

#News

#Assay development optimisation & technology #Drug discovery

Why kinetic assays are important to drug discovery

In this free webinar, Dr Nick Holliday, Chief Scientific Officer, Excellerate Bioscience will provide exclusive insight into the importance of kinetic assays in the drug discovery process. Viewers will gain knowledge on kinetic assay design and how to design assays that deliver hits with higher physiological relevance. Putting the dynamics… Read More

#Editor's Choice #News

#Covid-19 #Immunology / Virology & Vaccines

Interim clinical trial results of NIH-Moderna COVID-19 vaccine show 94% efficacy

The investigational NIH-Moderna COVID-19 vaccine mRNA-1273 has been found to be safe and effective at preventing symptomatic COVID-19 in adults. This is according to the interim results reviewed by an independent data and safety monitoring board (DSMB) overseeing the Phase III trial of the investigational COVID-19 vaccine mRNA-1273. The interim… Read More

#Covid-19 #Editor's Choice #News #Trending News

#Covid-19 #Immunology / Virology & Vaccines

Johnson & Johnson starts second global phase III trial of Janssen COVID-19 vaccine candidate

The Janssen COVID-19 vaccine candidate leverages the company’s AdVac technology platform, which was also used to develop and manufacture Janssen’s European Commission-approved Ebola vaccine and construct its Zika, RSV, and HIV investigational vaccine candidates. Janssen’s AdVac technology platform has been used to vaccinate more than 110,000 people to date across… Read More

#Covid-19 #Editor's Choice #News #Trending News

#Clinical trials #Diabetes #Drug repositioning

Diabetes drug can treat and reverse heart failure

Empagliflozin, a recently developed diabetes drug, can effectively treat and reverse heart failure in both diabetic and non-diabetic patients, according to researchers at the Icahn School of Medicine at Mount Sinai. Its clinical trial showed that this medication can improve the heart’s size, shape, and function, leading to better exercise… Read More

#News

#Antibiotics #Microbiome

Children who take antibiotics under 2 at risk of health conditions, says research

Children under age two  who take antibiotics are at greater risk for childhood-onset asthma, respiratory allergies, eczema, coeliac disease, obesity and attention deficit hyperactivity disorder, according to a paper written jointly by Mayo Clinic and Rutgers researchers. In a study published in the journal Mayo Clinic Proceedings, the… Read More

#News